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Abstract
Objective The prevalence of xeroderma pigmentosum (XP) is quite low in Europe, which may result in a delay in determining the
appropriate diagnosis. Furthermore, some subtypes of XP, including XPA, may manifest themselves with quite severe neurological
symptoms in addition to the characteristic dermatological lesions. Accordingly, the aim of the current study is to highlight the predom-
inant neurological aspects of XPA, as well as mild-to-moderate dermatological signs in a Hungarian family with 5 affected siblings.
Case reports The symptoms of the Caucasian male proband started to develop at 13–14 years of age with predominantly
cerebellar, hippocampal, and brainstem alterations. His elder sister and three younger brothers all presented similar, but less
expressed neurological signs. The diagnostic work-up, including clinical exome sequencing, revealed 2 novel compound het-
erozygous mutations (p.Gln146_Tyr148delinsHis, p.Arg258TyrfsTer5) in the XPA gene. Surprisingly, only mild-to-moderate
dermatological alterations were observed, and less severe characteristic ophthalmological and auditory signs were detected.
Conclusions In summary, we present the first family with genetically confirmed XPA in the Central-Eastern region of Europe,
clearly supporting the notion that disturbed function of the C-terminal region of the XPA protein contributes to the development
of age-dependent neurologically predominant signs. This case series may help clinicians recognize this rare disorder.
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Introduction
Xeroderma pigmentosum (XP) is a rare autosomal recessively
inherited condition with 100% penetrance [1] and only with a
prevalence of 2.3 per million in Western Europe [2]. There are
several distinct clinical subtypes of XP, including the variant
form and those marked with letters A–G based on the different
genetic cause. The characteristic cutaneous signs are exaggerated
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sensitivity to sunlight, early development of freckle-like
lentiginous pigmentation, and increased propensity for the for-
mation of malignant skin tumors. The ocular alterations may
involve conjunctival xerosis, corneal drying, and conjunctivitis.
Neurological signs, such as intellectual disability, speech distur-
bance, sensorineural hearing loss, peripheral neuropathy,
corticospinal alterations, and movement disorders with a pre-
dominant cerebellar ataxia resulting in severe walking disability,
may also develop, especially in XPA [1, 3]. The aim of the
current study is to present a family with 5 affected siblings diag-
nosed with novel compound heterozygous mutations in the XPA
gene in accordance with the CARE (CAse REport) guidelines
[4]. Additionally, this report is unique in its detailed genetical,
neuropathological, ophthalmological, and dermatopathological
assessment in addition to the comprehensive delineation of clin-
ical symptoms and signs. Accordingly, this case series may add
to the known phenotypic spectrum of XPA.
Case reports
Case histories, neurological, and related alterations
The Caucasian male proband (II-2 in Fig. 1), who died at
39 years of age, was first admitted to our clinic for a diagnostic
work-up of his unknown cognitive and movement disorder at
36 years of age. In addition to the presence of a slightly exag-
gerated sunburn reaction, his neurological symptoms started to
develop at his 13–14 years of age. His speech became slurred
and his cognitive functions deteriorated as well, resulting in
progressive and severe learning disabilities. He completed 11
classes and later he worked in a twine factory until his 26 years
of age, and then his disability led to retirement, and he became
dependent on his parents. Repeated falls occurred with scarring
and his swallowing functions and vision deteriorated as well.
Upon neurological examination, he presented signs of dis-
turbed eye movements (exophoria, restricted eye movements
in all directions with diplopia, gaze-evoked nystagmus),
dysarthria, hypo-/areflexia, pathological reflexes, and de-
creased sense of vibration. Furthermore, movement disorder
with dominating ataxia and parkinsonism (bilateral dysmetria,
cerebellar predominant mixed limb ataxiamore pronounced in
the legs, truncal ataxia, severe postural instability, broad-
based, ataxic gait, moderate, mainly left-sided bradykinesia
and upper limb dystonia, mild rigidity on provocation, mild
postural tremor, and occasional myoclonic jerks) was also
detected (Supplementary Material 1.1 and 2). The myoclonic
jerks were spontaneous, distal, and as they can be exacerbated
by sensory stimuli, they were presumed to be cortical. The
neuropsychological assessment revealed the signs of severe
cognitive dysfunction confined to two functional neuroana-
tomical networks, the hippocampus-dependent and that relat-
ed to the prefronto-cerebellar system, with similar degrees of
impairment (Supplementary Material 1.2).
The brainMRI revealed pronounced generalized atrophywith
slight predominance regarding the parieto-occipital and cerebel-
lar structures (Supplementary Material 1.3). The degree of atro-
phy seemed to correlate with the severity of neurological signs.
Electroneurography demonstrated mixed sensorimotor
lower limb predominant polyneuropathy.
Following his death caused by aspiration pneumonia
resulting from dysphagia as a part of progressive neurological
impairments, comprehensive post mortem neuropathological
assessment was carried out. The most prominent alterations
demonstrated by that were asymmetrical hippocampal sclero-
sis and Purkinje cell degeneration along with moderate loss of
neurons in the substantia nigra and a scattered infiltration of
CD8-positive T lymphocytes (for details, please see
Supplementary Material 1.4 and 1.5).
Regarding the family history of the proband, the presence
of similar, but less expressed, deterioration was identified in
his sister (II-1, 3 years older than the proband—
Supplementary Materials 1.6 and 3), and his three brothers
(II-3, 3 years younger than the proband—Supplementary
Materials 1.7 and 4; II-4, 5 years younger than the
proband—Supplementary Materials 1.8 and 5; II-5, 14 years
XPA gene
I-1 I-2
62 y 60 y
II-1 II-2 II-3 II-4 II-5







Fig. 1 Pedigree of the assessed
family with mutation in the XPA
gene
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younger than the proband—Supplementary Materials 1.9 and
6), respectively (Fig. 1). Besides a mild light sensitivity in the
father (I-1), there were no major relevant symptoms in the
parents; the demonstrated slight cognitive impairment may




Dermatological alterations generally include mild-to-moderate
solar damage on sun-exposed areas with the presence of hyper-
pigmentation in the basal keratinocytes and solid and infiltrative
basal cell carcinomas (Supplementary Material 1.10).
The results of the neurological and dermatological examina-
tions enabled staging of all 5 siblings according to the Japanese
Dermatological Association’s guideline (Table 1; [3]).
Ophthalmological assessment
Ophthalmological examinations demonstrated exophoria and
weakness of convergence with gaze-dependent diplopia in pa-
tients II-1 and II-2. Pathological alterations of the vitreo-macular
interface, i.e., thickened internal limiting membrane (ILM) with
ruffled inner surface in the macular area of the retina, were diag-
nosed in patients II-2, II-3, and II-4. This sign can be considered
as a gliotic proliferation of the inner surface of the ILM, although
epiretinal membrane formation could not be detected.
Diagnostic challenges and genomic studies
The major diagnostic challenges were that besides the severe
neurological symptoms and signs, the dermatological
alterations were not so prominent to be easily recognized by
a neurologist.
Variants obtained by exome sequencing (for details, please
see Supplementary Material 1.11) were filtered based on se-
verity and frequency against public variant databases includ-
ing dbSNP, ClinVar, ExAC, EVS, GnomAD, and an in-house
clinical exome database of 300 unrelated Hungarian samples.
F o r t h e t w o n e w X P A v a r i a n t s
( N M _ 0 0 0 3 8 0 . 3 : c . 4 3 8 _ 4 4 3 d e l A G A ATA ;
NP_000371 . 1 : p .G l n146_Ty r148de l i n sH i s a nd
NM_000380.3:c.772_785delCGTAAGACTTGTAC;
NP_000371.1:p.Arg258TyrfsTer5), ClinVar accessions
VCV000523609.1 and VCV000523609.1 were assigned, re-
spectively. The minor allele frequency (MAF) for XPA
c.438_443delAGAATA variant is unknown since it is not listed
in either the gnomAD (https://gnomad.broadinstitute.org/), ExAc
(http://exac.broadinstitute.org/), or in the EVS (https://evs.gs.
washington.edu/EVS/) databases. The MAF for XPA c.772_
785delCGTAAGACTTGTAC variant is 0.0000814 (23/
282538 allele) according to the gnomAD (https://gnomad.
broadinstitute.org/) database, which is within the range for a
pathogenic recessive allele. Based on the American College of
Medical Genetics andGenomics variant interpretation guidelines
[5], the first variant was classified as likely pathogenic, whereas
the second as pathogenic. The conservation of the region of XPA
protein affected by the in-frame mutation is demonstrated by
Supplementary Material 1.12.
Discussion
Regarding genotype-phenotype correlation, mutations affect-
ing exons 2, 3 and introns 1, 3 in the XPA gene are almost
Table 1 The staging of XPA
patients according to the
classification of the severity of XP
proposed by the Japanese
Dermatological Association’s
guidelines [3]
Patient II-1 Patient II-2 Patient II-3 Patient II-4 Patient II-5
Cutaneous symptom (D) score
Exaggerated sunburn 3 3 3 3 3
Freckle-like eruption 3 3 1 2 0
Skin cancer 3 2 0 0 0
Severity of cutaneous symptoms D3 D3 D2 D2 D2
Extracutaneous symptom (N) score
Hearing ability 1 N.A. 1 0 0
Movement 2 3 2 2 2
Intellectual functions 2 3 2 2 2
Swallowing and respiratory function 0 3 0 0 0
Severity of extracutaneous
symptoms
N3 N3 N3 N2 N2
Classification of XP depending on the severity
Stage 4 4 4 3 3
XP, xeroderma pigmentosum; N.A., not available
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always accompanied by severe characteristic clinical signs,
whereas mutation sites approaching the C-terminal of the cor-
responding XPA protein may be considered as hypomorphic,
i.e., they can be characterized by less severe neurological and
especially, dermatological phenotypes [6, 7] (the clinical and
demographic characteristics of all the published mutations in
the XPA gene were collected and outlined in Supplementary
Material 1.13). Indeed, cutaneous signs may be absent as well
[8]. In addition to the mutation site, the clinical phenotype
may be influenced by the age of the patient and, for dermato-
logical and ophthalmological alterations, by sun exposure as
well, even within the same family [9].
This genotype-phenotype correlation was confirmed
by the current study as well, i.e., only mild-to-moderate
dermatological and no prominent ophthalmological and
audiological, but severe neurological signs evolved with
age.
Despite the hypomorphic character of the reported
variants, the likely pathogenic feature of the in-frame
mutation in exon 4 (p.Gln146_Tyr148delinsHis) is sup-
ported by that it affects a conserved region of the protein
(presented in Supplementary Material 1.12) including
p.Glu147 and p.Tyr148, the deletion of which results in
the pathologically reduced binding of XPA protein to
replication protein A [10]. The second one in exon 6
(p.Arg258TyrfsTer5) may be considered pathogenic as it
eventuates a premature stop codon. In addition to its
frameshift character, the pathogenicity of this variant
may be further supported by a later unrelated report of
it in a patient with XPA (https://www.ncbi.nlm.nih.gov/
clinvar/variation/523608/).
Furthermore, in addition to the presentation of a very
detailed phenotypic description from a neurological point
of view, the present study yields several novelties: (1) 5
out of 5 affected siblings within a single family has not
been reported before, and this study presents the first
cases of XPA in the Central-Eastern region of Europe.
(2) Likely pathogenic novel in-frame and pathogenic
novel frameshift mutations in trans position are present-
ed. (3) A previously unreported scattered infiltration of
CD8+ T lymphocytes was detected in the proband with
XPA, without a manifest corresponding dermatological
alteration. In light of the fact that in common neurode-
generative diseases with accumulation of proteins, CD8+
cytotoxic T cells are not considered as hallmark lesions;
this finding is unexpected andmay be part of an immunological
activation following an insult from a currently uncharacterized
agent or process. However, the significance of this observation
could not be clarified in the present study and merits further
observations on similar cases.
In conclusion, the presentation of this unusual neurological
predominant phenotype of XPAmay help clinicians recognize
this rare disorder.
Acknowledgements Open access funding provided by University of
Szeged (SZTE).
Funding information This study was supported by the GINOP-2.3.2-15-
2 grant (TK, ZM), by the GINOP-2.3.2-15-2016-00034 and 20391-3/
2018/FEKUSTRAT grants (LV), by the OTKA125509 and GINOP-
2.3.2-15-2016-00020 grants (IBN), and by the National Brain Research
Program 2017-1.2.1-NKP-2017-00002_VI/4 (PK, LV) provided by The
National Research, Development and Innovation Office (Hungary). The
state funders played no role in the study design, data collection or anal-
ysis, decision to publish, or in the preparation of the manuscript. DZ and
IBN were supported by the János Bolyai Research Scholarship of the
Hungarian Academy of Sciences.
Compliance with ethical standards
Conflict of interest The authors declare that they have no conflict of
interest.
Ethical approval Written informed consent was obtained from all indi-
vidual participants included in the study. Additional informed consent
was obtained from all individual participants for whom identifying infor-
mation is included in this article (Regional Human Biomedical Research
Ethics Committee of the University of Szeged registration numbers are
150/2014. and 44/2016., respectively). All procedures performed in stud-
ies involving human participants were in accordance with the ethical
standards of the Regional Human Biomedical Research Ethics
Committee of the University of Szeged and with the 1964 Helsinki dec-
laration and its later amendments or comparable ethical standards.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a link
to the Creative Commons license, and indicate if changes were made.
References
1. Black JO (2016) Xeroderma pigmentosum. Head Neck Pathol 10:
139–144. https://doi.org/10.1007/s12105-016-0707-8
2. Kraemer KH, Lee MM, Scotto J (1987) Xeroderma pigmentosum.
Cutaneous, ocular, and neurologic abnormalities in 830 published
cases. Arch Dermatol 123:241–250
3. Moriwaki S, Kanda F, Hayashi M, Yamashita D, Sakai Y, Nishigori
C, Xeroderma pigmentosum clinical practice guidelines revision
committee (2017) Xeroderma pigmentosum clinical practice guide-
lines. J Dermatol 44:1087–1096. https://doi.org/10.1111/1346-
8138.13907
4. Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H, Riley D,
CARE Group* (2013) The CARE guidelines: consensus-based
clinical case reporting guideline development. Glob Adv Health
Med 2:38–43. https://doi.org/10.7453/gahmj.2013.008
5. Richards S, Aziz N, Bale S et al (2015) Standards and guidelines for
the interpretation of sequence variants: a joint consensus recom-
mendation of the American College of Medical Genetics and
Genomics and the Association for Molecular Pathology. Genet
Med Off J Am Coll Med Genet 17:405–424. https://doi.org/10.
1038/gim.2015.30
6. Takahashi Y, Endo Y, Sugiyama Y, Inoue S, Iijima M, Tomita Y,
Kuru S, Takigawa M, Moriwaki S (2010) XPA gene mutations
Neurol Sci
resulting in subtle truncation of protein in xeroderma pigmentosum
group A patients with mild skin symptoms. J Invest Dermatol 130:
2481–2488. https://doi.org/10.1038/jid.2010.137
7. Messaoud O, Rekaya MB, Ouragini H et al (2012) Severe pheno-
types in two Tunisian families with novel XPAmutations: evidence
for a correlation between mutation location and disease severity.
Arch Dermatol Res 304:171–176. https://doi.org/10.1007/s00403-
011-1190-4
8. Messaoud O, Ben Rekaya M, Kefi R, Chebel S, Boughammoura-
Bouatay A, Bel Hadj Ali H, Gouider-Khouja N, Zili J, Frih-Ayed
M, Mokhtar I, Abdelhak S, Zghal M (2010) Identification of a
primarily neurological phenotypic expression of xeroderma
pigmentosum complementation group A in a Tunisian family. Br
J Dermatol 162:883–886. https://doi.org/10.1111/j.1365-2133.
2010.09646.x
9. Kondoh M, Ueda M, Ichihashi M (1995) Correlation of the
clinical manifestations and gene mutations of Japanese
xeroderma pigmentosum group A patients. Br J Dermatol
133:579–585
10. Feltes BC, Bonatto D (2015) Overview of xeroderma pigmentosum
proteins architecture, mutations and post-translational modifica-
tions. Mutat Res Rev Mutat Res 763:306–320. https://doi.org/10.
1016/j.mrrev.2014.12.002
Publisher’s note Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional affiliations.
Neurol Sci
